Patients with serious infections that require iv antibiotic therorganizations (HMOs) [10] , the traditional Medicare fee-forservice program relies heavily on inpatient hospital care. For apy have traditionally been treated in the hospital setting. Over the past decade in the United States, however, increasing numexample, according to Medicare inpatient claims data, Ç650,000 Medicare beneficiaries were hospitalized with a pribers of these patients have received outpatient iv antibiotic therapy, with an estimated 300,000 treated in 1994 [1] . Recent mary diagnosis of pneumonia, endocarditis, cellulitis, or osteomyelitis in 1995 (table 1) . This reliance on hospital care is due, advances in antibiotic therapy [2] and vascular access [3] , as well as increasing acceptance of the therapy's safety and effiat least in part, to Medicare statutory provisions that prohibit coverage of most prescription drugs administered in the home cacy, have paved the way for this growth [4] . Many physicians now move patients out of the hospital once their condition is and outpatient setting. stabilized with an appropriate antibiotic regimen [5] . Indeed, Although patients can be reimbursed for iv antibiotics adsome physicians may prefer to forego hospitalization altoministered by a physician in his or her office, daily office visits gether, thus allowing patients to return to normal work or are not only inconvenient and time-consuming but also are not school routines [6, 7] and decreasing their chances of nosocofeasible for patients who require two or more infusions a day. mial infection or exposure to multidrug-resistant organisms [8] .
Moreover, iv antibiotics administered in the home, with the There is also some evidence that patients treated in ambulatory exception of those that require the use of durable medical settings return to work and usual function more rapidly [9] . equipment, are not covered by Medicare. The net result of these Medicare policies is the creation of disparate treatment patterns. Medicare patients receive mostly inpatient iv antibiSee editorial response by Wenzel and Nettleman otic therapy, while privately insured patients receive iv therapy on pages 1422 -3.
in both inpatient and outpatient settings. This study investigates the economic implications of a newly Although coverage of outpatient ambulatory care is common designed Medicare benefit for home-based iv antibiotic therapy. among private health plans and Medicare health maintenance Although the new program is essentially a home benefit, it differs significantly from the current Medicare home health benefit. To minimize confusion, the term ambulatory iv antibiReceived 27 March 1998; revised 22 July 1998.
otic therapy was coined to describe the benefit. new plan from current Medicare home coverage, which renursing facility, or outpatient) may vary. Figure 1 depicts the basic care patterns modeled under each scenario. Under the quires recipients to be homebound and in need of skilled nursing services.
current Medicare system, most patients are hospitalized to receive iv antibiotic therapy. Some remain in the hospital (3) All services necessary for self-administration of iv antibiotics are covered, including training and education of patients, throughout the entire treatment; others, once their condition is stabilized, receive care in a skilled nursing facility, a physiappropriate clinical services, supplies, laboratory tests, and durable medical equipment. It is anticipated that physicians and cian's office, or at home. In addition, some patients may receive all iv therapy in a physician's office. home health or home infusion companies will be best equipped to provide the new benefits. (4) Service providers will receive
In allowing self-administration of iv antibiotics at home, the a per diem payment plus reimbursement for drug costs, based new ambulatory iv antibiotic therapy benefit would change on the average wholesale price of the antibiotic. This payment current treatment pathways in two ways. Some stable patients design was viewed as reasonable for the scope of services would forego hospitalization altogether to receive all iv antprovided, on the basis of interviews with home health agencies iotics at home, and some inpatients would be discharged early and private insurers. As is the current policy for most outpatient to continue iv antibiotic treatment at home. Although most services, Medicare will cover 80% of per diem and drug costs, patients who are discharged early will be able to make the with patients responsible for the remaining 20%.
transition to the ambulatory benefit, those who require more advanced care will go to a skilled nursing facility. However, patients who need home health care in addition to iv antibiotics Methods will not be covered by the new ambulatory iv therapy benefit. The new model also includes adjustments for a ''woodwork'' Medicare costs associated with treating the four medical effect. This term is commonly used for unexpected cost effects conditions (cellulitis, pneumonia, osteomyelitis, and endocardithat ''come out of the woodwork.'' In this case it would apply tis) were estimated on the basis of both the current Medicare to a change in behavior, where physicians might prescribe benefits structure and the proposed new benefits structure that ambulatory iv antibiotic therapy for patients who would otherincludes ambulatory iv antibiotics. The new model assumes a wise have received oral antibiotic treatment, either because of specific duration of antibiotic treatment (in days) for each medical condition, although the treatment setting (inpatient, skilled easier access to iv therapy or because oral antibiotic therapy / 9c5c$$de23 11-13-98 16:30:35 cidas UC: CID would not be covered. To account for this phenomenon, the hospitalization assumed to drop from current Medicare averages to levels for non-Medicare patients (an assumption supmodel assumes the benefit would cover 10% more patients than are currently receiving treatment under Medicare.
ported by interviews with three medical directors of private and Medicare risk plans). Table 2 summarizes cost estimates Parameter estimates for the new model came from three principal sources: the clinical literature, claims databases, and and their sources. To predict changes in Medicare expenditures over several a panel of infectious disease experts. Two national claims databases, the National Hospital Discharge Survey (NHDS) and years, the model incorporates the March 1997 Congressional Budget Office (CBO) growth forecasts for Medicare enrollment the Medicare Provider Analysis and Review (MEDPAR) file, were used to determine length of stay and number of admisand costs, as well as an assumed 5% annual price increase for iv antibiotics. sions for privately insured and Medicare beneficiaries with the four targeted infections.
The NHDS database contains hospital discharge data from Results a random sampling of inpatient, short-stay, nongovernmental hospitals in the United States. The MEDPAR file contains Figure 2 displays projected Medicare expenditures over 10 years under both current and proposed benefit plans. For the hospital discharge data for all Medicare beneficiaries using inpatient hospital services. Four nationally recognized infecnew benefit, the graph displays costs by major resource component. Table 3 summarizes the savings generated by the new tious disease physicians were surveyed to identify current treatment pathways for the four target conditions and likely changes benefit. Inpatient hospitalization frequency and costs decline over time as the new ambulatory iv antibiotic benefit phases in treatment patterns that would be created by the new benefit. of private-pay patients. By year 3, coverage of ambulatory not be decreased to the level forecast in the model, Medicare savings will be significantly diminished. For example, a 25% therapy saves the Medicare program $369 million and fully recoups the costs associated with implementation. Five-year reduction in eliminated hospitalizations will produce savings of $514 million, $875 million less than the baseline estimate. If cumulative savings associated with the new benefit are nearly $1.4 billion. the benefit reduces hospitalizations by only 50% of the forecast reduction, Medicare expenditures will increase by $362 million The magnitude of the Medicare savings is directly tied to a number of factors, including the number of hospitalizations over 5 years, since the reduction in hospitalizations would not be sufficient to pay for the new benefit's phase-in cost. that can be eliminated, the ambulatory iv antibiotic per diem rate, the number of patients who receive both inpatient hospiAlthough Medicare savings would be reduced by increases in the ''woodwork'' effect and per diem rate over time, program tal care and ambulatory therapy, and the ''woodwork'' effect. Sensitivity analyses conducted to determine the effect of savings remain significant. It is interesting to note that if the Medicare population fails to achieve the shorter length of stay these variables on Medicare expenditures are summarized in table 4. common for privately insured patients, overall Medicare savings will actually increase, because patients who remain hospiThe majority of the Medicare savings is achieved by the elimination of hospital stays. Thus, if hospital admissions cantalized require less ambulatory iv antibiotic therapy.
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Discussion
The proposed ambulatory iv antibiotic therapy benefit can reduce Medicare expenditures while providing good clinical The huge potential Medicare savings associated with a new outcomes. Moreover, hospitals would continue to benefit since ambulatory iv benefit underscores the present outdated Mediunder the Medicare diagnosis-related group (DRG) system, care coverage policies for outpatient antibiotic therapy. The they are paid a fixed amount per case, regardless of how long program pays for inpatient care but excludes equally effective, a patient is hospitalized. For each day of inpatient care elimiless costly outpatient alternatives. This situation not only ignated by early discharge to ambulatory iv therapy, a hospital nores the wide acceptance of outpatient iv antibiotic therapy may realize savings of $200 -$400/day [18] , savings that, acby the medical community and private health plans but also cording to our cost model, could reach $5 billion to $6 billion illustrates the need for a change in Medicare's benefit structure, over 5 years. which fails to take advantage of cost-effective medical adThus, overall potential savings associated with the new benevances. Medicare's blanket prohibition of outpatient self-adfit are significant and consistent with findings in the literature ministered drugs also is inconsistent with recent congressional [19 -21] . These savings are based on model assumptions, howefforts to provide more care options to Medicare beneficiaries ever. To evaluate the validity of model results, it is crucial to and to slow the increase in Medicare expenditures.
understand both those assumptions and the limitations they impose. First, model results are predicated on the March 1997 CBO hospital and ambulatory iv therapy. Furthermore, a panel of coverage of ambulatory therapy could also result in substantial cost savings. Furthermore, the new benefit would be fully selfinfectious disease and Medicare reimbursement experts have reviewed the model's assumptions.
financing. As Congress and the President continue to consider Medicare program changes that will reduce expenditures and Third, the model assumes a 3-year phase-in period. It is not known how long the medical community will require to adjust expand beneficiaries' care options, an ambulatory iv antibiotic benefit that meets both goals should receive serious considerpractice patterns. The program savings demonstrated in the model are tied directly to the reduced use of hospital care; ation. therefore, educational efforts may be needed to help physicians feel comfortable with the early discharge of elderly patients to
